22.23
-0.33 (-1.46%)
| Penutupan Terdahulu | 22.56 |
| Buka | 22.48 |
| Jumlah Dagangan | 652,401 |
| Purata Dagangan (3B) | 737,385 |
| Modal Pasaran | 662,822,976 |
| Harga / Jualan (P/S) | 6.08 |
| Harga / Buku (P/B) | 20.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 |
| Margin Keuntungan | -125.70% |
| Margin Operasi (TTM) | -99.16% |
| EPS Cair (TTM) | -4.92 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 286.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,016.89% |
| Nisbah Semasa (MRQ) | 8.25 |
| Aliran Tunai Operasi (OCF TTM) | -108.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.04 M |
| Pulangan Atas Aset (ROA TTM) | -15.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -343.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | AnaptysBio, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.06% |
| % Dimiliki oleh Institusi | 134.17% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 90.00 (Guggenheim, 304.86%) | Beli |
| Median | 40.00 (79.94%) | |
| Rendah | 38.00 (HC Wainwright & Co., 70.94%) | Beli |
| Purata | 56.00 (151.91%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 21.29 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Jun 2025 | 38.00 (70.94%) | Beli | 21.27 |
| Guggenheim | 28 May 2025 | 90.00 (304.86%) | Beli | 20.90 |
| 06 May 2025 | 54.00 (142.91%) | Beli | 20.12 | |
| Wedbush | 01 May 2025 | 40.00 (79.94%) | Beli | 21.70 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Jun 2025 | Pengumuman | Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA |
| 27 May 2025 | Pengumuman | Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 |
| 05 May 2025 | Pengumuman | Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update |
| 24 Mar 2025 | Pengumuman | Anaptys Announces Stock Repurchase Plan |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |